Episode Details

In this episode, we delve into the key clinically relevant abstracts in leukemia and myeloid neoplasms with Dr. Jayastu Senapati from the MD Anderson Cancer Center. Here are the links to the abstracts we discussed: 

Older AML: Ven+HMA vs 7+3

Abstract 450: https://ash.confex.com/ash/2024/webprogram/Paper210320.html

Abstract 971: https://ash.confex.com/ash/2024/webprogram/Paper202801.html

Abstract 969: https://ash.confex.com/ash/2024/webprogram/Paper199267.html

Venetoclax resistance mechanisms

https://pubmed.ncbi.nlm.nih.gov/39478230/

FLAG-GO vs FLAG-IDA 

https://ashpublications.org/blood/article/144/Supplement%201/1513/532742/Gemtuzumab-Ozogamicin-Added-to-Fludarabine

 CPX-351: 

Abstract 55: https://ash.confex.com/ash/2024/webprogram/Paper207094.html

Abstract 60: https://ash.confex.com/ash/2024/webprogram/Paper200413.html

Menin Inhibitors 

Abstract 211 https://ash.confex.com/ash/2024/webprogram/Paper194384.html

Abstract 212 https://ash.confex.com/ash/2024/webprogram/Paper207106.html

Abstract 213 https://ash.confex.com/ash/2024/webprogram/Paper194827.html

Abstracts 214 https://ash.confex.com/ash/2024/webprogram/Paper198218.html

Abstract 215 https://ash.confex.com/ash/2024/webprogram/Paper198218.html

Abstract 216 https://ash.confex.com/ash/2024/webprogram/Paper204375.html

FLT3 inhibitors
Abstract 221: https://ash.confex.com/ash/2024/webprogram/Paper201595.html

MDS

 Abstract 349: https://ash.confex.com/ash/2024/webprogram/Paper194510.html

ATRA in MDS:  

https://ash.confex.com/ash/2024/webprogram/Paper200433.html